Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2006-12-01. The firm is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. The company is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.

Industry: Pharmaceutical Preparations Peers: Xenon Pharmaceuticals Inc